# US 2026/0275344 A1 · Circular single-stranded dna molecules for recombinase-based gene editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0275344 A1
- Document ID: US20260275344A1
- Status: Published application
- Kind: A1
- Application number: 19/472,952
- Filed: 2024-04-05
- Published: 2026-09-17
- Earliest claimed: 2023-04-06
- Assignees: Fc IP Holdings, LLC
- Applicants: FC IP Holdings, LLC
- Inventors: Keqiang XIE; Richard SHAN; Hao WU
- Web page: https://patentgrep.com/patent/US20260275344A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 1/20: Bacteria; Culture media therefor
- C12N 5/04: Plant cells or tissues {(culture media C12N5/0025)}
- C12N 5/0602: {Vertebrate cells}
- C12N 9/1241: {Nucleotidyltransferases (2.7.7)}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/1003: {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/85: for animal cells
- C12N 15/907: {in mammalian cells}
- C12Y 207/07: Nucleotidyltransferases (2.7.7)
- C12N 2310/11: Antisense
- C12N 2310/52: branched
- C12N 2310/532: Closed or circular
- C12N 2800/107: for mammalian
- C12N 2800/30: Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N 2830/34: being a transcription initiation element
- C12N 2830/36: being a transcription termination element
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Described herein is a circular single-stranded DNA (cssDNA) molecule suitable for recombinase-based gene editing. Also described herein is a double-stranded DNA (dsDNA) molecule and a kit including the same for preparing the cssDNA molecule, as well as a kit and a method for performing genome editing using the cssDNA or the dsDNA.

## Claims

### Claim 1

A circular single-stranded DNA (cssDNA) molecule comprising a recombinase recognition sequence recognized by a recombinase.

### Claim 2 (depends on 1)

The cssDNA molecule of claim 1, wherein at least one of the following applies:
(a) the recombinase is a site-specific recombinase (SSR),
(b) the site-specific recombinase is a tyrosine integrase, a serine integrase, or a site-specific transposase,
(c) the recombinase recognition sequence is a locus of X-over P1 (loxP) sequence, a flippase recognition target (FRT) sequence, a rox sequence, an attachment-phage (attP) sequence, an attachment-bacteria (attB) sequence, an attachment-left (attL) sequence, an attachment-right (attR) sequence, a VloxP sequence, a vox sequence, or a transposase recognition inverted terminal repeat (ITR),
(d) the cssDNA molecule further comprises a payload sequence, optionally wherein the payload sequence encodes an RNA molecule or a polypeptide, optionally wherein the payload sequence comprises a length of about 1 nucleotide to about 50,000 nucleotides,
(e) the cssDNA molecule is purified or enriched.

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

A double stranded DNA (dsDNA) molecule comprising:
a template sequence encoding a cssDNA comprising a recombinase recognition sequence recognized by a recombinase; and
a cssDNA conversion sequence.

### Claim 10 (depends on 9)

The dsDNA molecule of claim 9, wherein at least one of the following applies:
(a) the double stranded DNA molecule is a linear dsDNA molecule or a circular dsDNA molecule,
(b) the cssDNA conversion sequence is a sequence originated or derived from an M13 phage f1 origin, an M13 phage replication initiator, an M13 phage replication terminator, or an M13 phage packing signal (PS),
(c) the dsDNA molecule further comprises a payload sequence, or a payload sequence insertion site for inserting the payload sequence, optionally wherein the payload insertion site is a multiple cloning site,
(d) the dsDNA molecule is one single DNA molecule, or two or more separate DNA molecules.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A kit comprising:
the cssDNA molecule of claim 1; and
a recombinase or a nucleic acid encoding the recombinase,
wherein the recombinase recognizes the recombinase recognition sequence of the cssDNA.

### Claim 16 (depends on 15)

The kit of claim 15, wherein at least one of the following applies:
(a) the recombinase is a serine integrase, a tyrosine integrase, or a site-specific transposase,
(b) the recombinase comprises at least one selected from the group consisting of Cre, Flp, Dre, SCre, VCre, Vika, B2, B3, KD, ΦC31, Bxb1, RDF, λ, HK022, HP1, γδ, ParA, Gin, R4, TP901-1, TG1, PhiRv1, PhiBT1, SprA, XisF, TnpX, R, A118, spoIVCA, MR11, SCCmec, TndX, XerC, XerD, XisA, Hin, Cin, mrpA, beta, PhiFC1, Fre, Clp, sTre, FimE, HbiF, φFC1, φC1, q 370.1, Wβ, BL3, SPBc, K38, Peaches, Veracruz, Rebeuca, Theia, Benedict, KSSJEB, PattyP, Doom, Scowl, Lockley, Switzer, Bob3, Troube, Abrogate, Anglerfish, Sarfire, SkiPole, ConceptII, Museum, Severus, Airmid, Benedict, Hinder, ICleared, Sheen, Mundrea, BxZ2, φRV, retrotransposases encoded by R2, L1, Tol2 Tc1, Tc3, Mariner (Himar 1), Mariner (mos 1), Minos, R1, R2, R3, R4, R5, Mu transposase, Tn3 transposase, Tn5 transposase, Tn7 transposase, Tol2, Sleeping Beauty transposase, and PiggyBac transposase,
(c) the kit comprises the nucleic acid encoding the recombinase, wherein the nucleic acid encoding the recombinase is an mRNA, a single stranded DNA, or a double stranded DNA,
(d) the kit comprises the nucleic acid encoding the recombinase, and wherein the nucleic acid encoding the recombinase is part of the cssDNA molecule or the dsDNA molecule,
(e) the kit further comprises a component for introducing the cssDNA, and the recombinase or the nucleic acid encoding the recombinase, into the cell.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 15)

The kit of claim 15, further comprising an oligonucleotide fully or partially complementary with the cssDNA molecule.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the oligonucleotide is a primer that converts the cssDNA molecule to a circular double stranded DNA molecule inside a cell, optionally wherein the oligonucleotide comprises a length of about 5 nucleotides to about 200 nucleotides.

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 15)

A system comprising:
the kit of claim 15; and
a cell to be engineered.

### Claim 25 (depends on 24)

The system of claim 24, wherein at least one of the following applies:
(a) a genomic DNA or a mitochondrial DNA of the cell comprises a landing pad sequence for the integration of the cssDNA molecule into the genomic DNA or the mitochondrial DNA,
(b) the cell is a bacterial cell, a plant cell, or a mammalian cell,
(c) the cell is an isolated cell, a cell from a cell line, a primary cell, or a cell in a subject,
(d) the cell is a pluripotent stem cell, an induced pluripotent stem cell (iPSCs), a hematopoietic stem cell (HSCs), a B-cell, a T-cell, a natural killer (NK) cell, or a terminally differentiated non-dividing cell, optionally wherein the terminally differentiated non-dividing cell is a neuron, a muscle, or a hepatocyte.

### Claim 26 (depends on 25)

The system of claim 25, wherein the landing pad sequence is recognized by the recombinase such that the recombinase opens up the cssDNA molecule and inserts the linearized cssDNA molecule into the genomic DNA or the mitochondrial DNA using the landing pad sequence as an anchor site, optionally the landing pad sequence is a locus of X-over P1 (loxP) sequence, a flippase recognition target (FRT) sequence, a rox sequence, an attachment-phage (attP) sequence, an attachment-bacteria (attB) sequence, an attachment-left (attL) sequence, an attachment-right (attR) sequence, a VloxP sequence, a vox sequence, or a transposase recognition inverted terminal repeat (ITR).

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30

(canceled)

### Claim 31 (depends on 1)

A method for performing genetic engineering in a cell, comprising introducing into the cell:
the cssDNA of claim 1; and
a recombinase or a nucleic acid encoding the recombinase,
wherein the recombinase recognizes the recombinase recognition sequence of the cssDNA to integrate the cssDNA into a genomic DNA or a mitochondrial DNA of the cell.

### Claim 32 (depends on 31)

The method of claim 31, wherein at least one of the following applies:
(a) the recombinase is a serine recombinase, a tyrosine recombinase, or a site-specific transposase,
(b) the recombinase is Cre, Flp, Dre, SCre, VCre, Vika, B2, B3, KD, ΦC31, Bxb1, RDF, λ, HK022, HP1, γδ, ParA, Gin, R4, TP901-1, TG1, PhiRv1, PhiBT1, SprA, XisF, TnpX, R, A118, spoIVCA, MR11, SCCmec, TndX, XerC, XerD, XisA, Hin, Cin, mrpA, beta, PhiFC1, Fre, Clp, sTre, FimE, HbiF, φFC1, φC1, q 370.1, Wβ, BL3, SPBc, K38, Peaches, Veracruz, Rebeuca, Theia, Benedict, KSSJEB, PattyP, Doom, Scowl, Lockley, Switzer, Bob3, Troube, Abrogate, Anglerfish, Sarfire, SkiPole, ConceptII, Museum, Severus, Airmid, Benedict, Hinder, ICleared, Sheen, Mundrea, BxZ2, φRV, retrotransposases encoded by R2, L1, Tol2 Tc1, Tc3, Mariner (Himar 1), Mariner (mos 1), Minos, R1, R2, R3, R4, R5, Mu transposase, Tn3 transposase, Tn5 transposase, Tn7 transposase, Tol2, Sleeping Beauty transposase, or PiggyBac transposase,
(c) the method comprises introducing into cells a sense stranded cssDNA, an antisense stranded cssDNA, or a mixture of both,
(d) the cell is a bacterial cell, a plant cell, or a mammalian cell,
(e) the cell is an isolated cell, a cell from a cell line, a primary cell, or a cell in a subject,
(f) the cell is a pluripotent stem cell, an induced pluripotent stem cell (iPSCs), a hematopoietic stem cell (HSCs), a B-cell, a T-cell, a natural killer (NK) cell, or a terminally differentiated non-dividing cell, optionally wherein the terminally differentiated non-dividing cell is a neuron, muscle, or hepatocyte.

### Claim 33

(canceled)

### Claim 34 (depends on 31)

The method of claim 31, further comprising introducing into the cell an oligonucleotide fully or partially complementary to at least a portion of the cssDNA molecule.

### Claim 35 (depends on 34)

The method of claim 34, wherein a cellular machinery of the cell converts the cssDNA molecule into a circular double stranded DNA molecule using the oligonucleotide as a primer.

### Claim 36 (depends on 34)

The method of claim 34, wherein the oligonucleotide comprises a length of about 5 nucleotides to about 200 nucleotides.

### Claim 37

(canceled)

### Claim 38 (depends on 31)

The method of claim 31, wherein the genomic DNA or the mitochondrial DNA of the cell comprises a landing pad sequence for the integration of the cssDNA molecule into the genomic DNA or the mitochondrial DNA.

### Claim 39 (depends on 38)

The method of claim 38, wherein at least one of the following applies:
(a) further comprising culturing the cell under a condition sufficient for the landing pad sequence to be recognized by the recombinase and for the recombinase to open up the cssDNA molecule and insert the linearized cssDNA molecule into the genomic DNA or the mitochondrial DNA using the landing pad sequence as an anchor site,
(b) the landing pad sequence is a locus of X-over P1 (loxP) sequence, a flippase recognition target (FRT) sequence, a rox sequence, an attachment-phage (attP) sequence, an attachment-bacteria (attB) sequence, an attachment-left (attL) sequence, an attachment-right (attR) sequence, a VloxP sequence, a vox sequence, or a transposase recognition inverted terminal repeat (ITR).

### Claim 40

(canceled)

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43

(canceled)
